Oral norovirus vaccine shows positive results in phase 2 clinical trial
According to the results of a phase 2 trial, an oral norovirus vaccine generated a strong mucosal immune response and even reduced viral shedding in vaccinated volunteers. Signs of the vaccine's efficacy support its potential to address the lack of safe and reliable vaccines against this virus, which is a major cause of gastrointestinal infections worldwide. The results were published today in the journal Science Translational Medicine.
0